Somalogic Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Somalogic Inc (SLGC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Somalogic Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 82M vs 87,105M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+7.9% annualized vs trailing 12 months), vs decelerating (-10.2%) for its tracked peer group.
- Growth: Somalogic Inc generated -47.1% revenue growth year over year in Q3 2023, vs -4.4% for its competitors combined.
- Profitability: Its -100.5% net margin compares with 9.4% for the peer group.
- Peer revenue share: Somalogic Inc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.17M compares with $0.38M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SLGC Sales vs. its Competitors, Q3 2023
Somalogic Inc reported revenue contraction of 47.14 % year on year in Q3 2023, below its competitors' combined revenue change of -4.39 %.
With a net margin of -100.49 %, Somalogic Inc reported lower profitability than its competitors (9.41 %).
Somalogic Inc generated 0.11 % of the combined sales of its peer group, down from 0.20 % a year earlier.
API endpoints for this dataset
Somalogic Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Somalogic Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Somalogic Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Somalogic Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Somalogic Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 9.0% year over year, combined, vs -47.1% for Somalogic Inc. Somalogic Inc's share of combined industry revenue moved from 0.08% to 0.04%, a loss of 0.04 percentage points.
Somalogic Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Somalogic Inc | - | No | No | Yes |
| Competitors combined (11) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SLGC Stock Performance relative to its Competitors
SLGC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Illumina Inc | 282.9% | Outperformed |
| 2 | Fortrea Holdings Inc | 282.9% | Outperformed |
| 3 | Bio rad Laboratories Inc | 282.9% | Outperformed |
| 4 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
| 5 | Agilent Technologies inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Somalogic Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Somalogic Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Somalogic Inc |
392.85 | 81.72 |
 Thermo Fisher Scientific Inc |
260,827.84 | 47,351.00 |
 Agilent Technologies inc |
49,101.92 | 7,372.00 |
 Ge Healthcare Technologies Inc |
37,528.78 | 19,878.00 |
 Illumina Inc |
31,784.83 | 4,538.00 |
 Bio rad Laboratories Inc |
10,146.41 | 2,593.00 |
| SUBTOTAL | 392,898.15 | 87,186.55 |
Sign in to see all competitors of Somalogic Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Somalogic Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Somalogic Inc's Competitors Named by the Company
Competitive relationships identified from Somalogic Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Quantum si Incorporated | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Olink Holding Ab publ | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Enzo Biochem Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Somalogic Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Somalogic Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
| Agilent Technologies inc | Agilent CrossLab 41.36 % |
| Ge Healthcare Technologies Inc | Radiology Subsegment 44.68 % |
| Illumina Inc | Sequencing 90.43 % |
| Bio rad Laboratories Inc | Clinical Diagnostics 59.96 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Somalogic Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Somalogic Inc | 393 | 173,881 | -277,409 |
| Thermo Fisher Scientific Inc | 260,828 | 378,808 | 56,712 |
| Agilent Technologies inc | 49,102 | 407,293 | 79,558 |
| Ge Healthcare Technologies Inc | 37,529 | 368,111 | 40,537 |
| Illumina Inc | 31,785 | 3,545,313 | 699,219 |
| Bio rad Laboratories Inc | 10,146 | 348,054 | 137,302 |
| PEERS TOTAL | 392,505 | 383,392 | 50,436 |
Somalogic Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Agilent Technologies inc | Americas 41.63 % |
| Illumina Inc | United States and Canada 56.42 % |
| Bio rad Laboratories Inc | UNITED STATES 41.39 % |
| Fortrea Holdings Inc | North America 47.14 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Somalogic Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 46.70 % | 33.07 % (avg) | +13.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -5.80 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 5.67 % | 7.44 % (avg) | -1.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Somalogic Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.0x | - |
| EV / EBITDA | - | 21.1x | - |
| P/B | 0.8x | 4.4x | -3.6x |
| Return on Equity | -24.72 % | industry aggregate | -24.05 % |
| Return on Invested Capital | -13.66 % | -7.68 % (avg) | -5.98 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Somalogic Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 5.67 % vs industry average 7.44 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Somalogic Inc's dedicated Suppliers and Customers pages, not here.
Somalogic Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+7.9% annualized vs trailing 12 months).
Weaknesses
- Return on equity 24.1 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (30.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-10.2% annualized).
Methodology: see Methodology: SWOT Analysis.
Somalogic Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Somalogic Inc | 10.75 | 15.12 | - |
| Thermo Fisher Scientific Inc | 0.39 | 1.69 | 0.81 |
| Agilent Technologies inc | 0.77 | 2.02 | 1.02 |
| Ge Healthcare Technologies Inc | 0.14 | 1.29 | 0.92 |
| Illumina Inc | - | 2.02 | 0.68 |
| Bio rad Laboratories Inc | 0.60 | 3.55 | 0.22 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Somalogic Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Somalogic Inc | Q3 2023 | -47.1 % | - |
| Thermo Fisher Scientific Inc | Q3 2026 | +9.1 % | +6.2 % |
| Agilent Technologies inc | Q2 2026 | +8.1 % | +7.7 % |
| Ge Healthcare Technologies Inc | Q3 2026 | +29.4 % | +32.5 % |
| Illumina Inc | Q3 2026 | +4.2 % | +46.7 % |
| Bio rad Laboratories Inc | Q3 2026 | +0.6 % | - |
| PEERS TOTAL | +12.3 % | +72.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Somalogic Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Somalogic Inc | Q3 2023 | -11.3 % | -51.2 % |
| Thermo Fisher Scientific Inc | Q3 2026 | +133.0 % | +8.2 % |
| Agilent Technologies inc | Q2 2026 | -1.6 % | -22.3 % |
| Ge Healthcare Technologies Inc | Q3 2026 | +188.1 % | +3.6 % |
| Illumina Inc | Q3 2026 | -14.8 % | +29.0 % |
| Bio rad Laboratories Inc | Q3 2026 | +6.1 % | -1.6 % |
Somalogic Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Somalogic Inc | - | - | - |
| Thermo Fisher Scientific Inc | 6.29% | 7.46% | 13.32% |
| Agilent Technologies inc | 10.97% | 19.84% | 41.99% |
| Ge Healthcare Technologies Inc | 5.85% | 7.60% | 20.04% |
| Illumina Inc | 13.43% | 18.74% | 31.45% |
| Bio rad Laboratories Inc | 9.88% | 10.59% | 14.07% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Somalogic Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Somalogic Inc | - | 4.81 |
| Thermo Fisher Scientific Inc | 37.16 | 5.51 |
| Agilent Technologies inc | 34.22 | 6.66 |
| Ge Healthcare Technologies Inc | 17.63 | 1.89 |
| Illumina Inc | 35.65 | 7.00 |
| Bio rad Laboratories Inc | 9.99 | 3.91 |
| PEERS AVERAGE | 34.68 | 4.51 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.